CJJK(SZ:002435)2023-10-25 16:00Financial Performance - The company's revenue for Q3 2023 was ¥783,574,732.34, a decrease of 17.68% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥6,957,402.83, representing a decline of 142.49% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥14,411,937.17, down 235.28% from the previous year[5]. - Total operating revenue for Q3 2023 was CNY 2,532,143,721.26, a decrease of 7.95% compared to CNY 2,750,789,217.12 in the same period last year[19]. - The net loss for the period was CNY 25,727,151.73, an improvement from a loss of CNY 92,894,942.51 in the previous year[17]. - The net profit for Q3 2023 was CNY 48,132,464.28, a decrease of 50.5% compared to CNY 97,283,921.32 in Q3 2022[20]. - Operating profit for Q3 2023 was CNY 81,878,046.09, down 34.6% from CNY 125,364,750.55 in the same period last year[20]. - The company reported a total comprehensive income of CNY 48,760,130.52 for Q3 2023, compared to CNY 99,645,489.82 in Q3 2022[21]. - Basic and diluted earnings per share for Q3 2023 were both CNY 0.0543, down from CNY 0.0868 in Q3 2022[21]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥8,011,469,155.43, an increase of 8.68% compared to the end of the previous year[5]. - Total current assets as of September 30, 2023, amount to ¥2,598,273,125.24, an increase from ¥1,680,084,001.51 at the beginning of the year[15]. - Total liabilities reached CNY 3,386,064,762.57, an increase of 24.36% compared to CNY 2,721,908,162.82 last year[17]. - The company's total assets amounted to CNY 8,011,469,155.43, rising from CNY 7,371,749,936.56, indicating a growth of 8.68%[17]. - The company's equity attributable to shareholders was CNY 4,564,453,571.67, slightly down from CNY 4,566,143,998.28[17]. Cash Flow and Investments - Cash and cash equivalents increased by 54.65% to ¥2,598,273,125.24, primarily due to increased borrowings[9]. - Cash flow from operating activities was CNY 253,126,004.74, down 26.9% from CNY 346,455,455.66 in Q3 2022[23]. - The company's investment activities generated a net cash flow of CNY 138,127,407.18 in Q3 2023, a significant improvement from a net outflow of CNY 204,577,325.31 in Q3 2022[23]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 44,270[11]. - The largest shareholder, Changjiang Runfa Group, holds 27.09% of shares, amounting to 334,831,965 shares, with 206,334,000 shares pledged[11]. - The second largest shareholder, Zhongshan Songde Zhangjiagang Free Trade Zone Pharmaceutical Industry Equity Investment Partnership, holds 9.84% of shares, totaling 121,607,997 shares[11]. Research and Development - Research and development expenses rose by 57.18% to ¥48,112,588.36, reflecting increased payments for R&D progress[9]. - Research and development expenses increased to CNY 48,112,588.36, up 57.2% from CNY 30,609,395.13 in Q3 2022[20]. - The company has not disclosed any new product or technology developments in the current report[13]. Other Financial Metrics - The company’s basic and diluted earnings per share were both -¥0.0056, a decrease of 142.42% year-on-year[5]. - The company’s weighted average return on equity was -0.15%, down 0.51% from the previous year[5]. - The company experienced a 151.90% increase in notes payable, reaching ¥499,660,163.45, attributed to increased note payments[9]. - Deferred tax assets rose to CNY 37,605,371.98 from CNY 26,141,130.84, marking an increase of 43.83%[16]. Operational Highlights - Total operating costs for Q3 2023 were CNY 2,460,592,081.80, down 7.37% from CNY 2,656,160,312.15 year-over-year[19]. - Inventory increased to CNY 623,906,043.30 from CNY 611,431,418.41, reflecting a growth of 2.42%[16]. - Accounts receivable increased to ¥289,770,431.60 from ¥278,298,060.78 at the beginning of the year[15]. - Prepayments rose to ¥353,300,961.59 from ¥262,657,207.71 at the beginning of the year[15]. - The company reported a decrease in trading financial assets from ¥837,815,996.51 to ¥484,097,984.35[15]. Corporate Governance - The third quarter report of Changjiang Runfa Health Industry Co., Ltd. is unaudited[25]. - The board of directors meeting was held on October 26, 2023[26]. - There are no significant mergers or acquisitions reported in the current quarter[13].